<DOC>
	<DOCNO>NCT00152386</DOCNO>
	<brief_summary>Patients assign one three treatment group . Study medication administer 52 week study duration .</brief_summary>
	<brief_title>A Placebo Controlled Study Assess Efficacy Safety Certolizumab Pegol Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Male female , age least 18 year old Screening visit . A clear chest Xray within 3 month prior Baseline visit . A diagnosis adultonset RA ( least six month duration longer 15 year prior Screening ) define 1987 American College Rheumatology classification criterion . Active RA disease Screening Baseline define : ≥9 tender joint . ≥9 swollen joint . fulfil 1 follow 2 criterion : ≥30 mm/hour ESR ( Westergren ) , CRP &gt; 15 mg/L . Must receive stable dose MTX without folic acid least 3 month prior Baseline visit . The minimum dose 10 mg MTX weekly . Patient must willing attend Week 52 Xray hand foot even longer receive study treatment withdrawn inform consent . A diagnosis inflammatory arthritis e.g. , psoriatic arthritis ankylose spondylitis . A secondary , noninflammatory type arthritis ( e.g . OA fibromyalgia ) Investigator 's opinion symptomatic enough interfere evaluation effect CDP870 patient 's primary diagnosis RA . A history infect joint prosthesis time prosthesis still situ . Does meet exclusionary concomitant medication criterion . A history lymphoproliferative disorder include lymphoma sign symptom suggestive lymphoproliferative disease time . Patients high risk infection Investigator 's opinion ( e.g . leg ulcer , indwell urinary catheter persistent recurrent chest infection ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Rheumatoid Arthritis , CDP870</keyword>
	<keyword>Certolizumab pegol , Cimzia</keyword>
</DOC>